Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 58

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 58
---
3,409 19 %Salaries26,531 16 %24,532 16 %1,999 8 %Facilities related6,457 4 %7,132 4 %(675)(9)%Total research and development expense, excluding non-cash expense$149,038 91 %$140,921 92 %$8,117 6 %Stock compensation7,612 5 %7,241 5 %371 5 %Depreciation and amortization5,718 4 %4,269 3 %1,449 34 %Total research and development expense$162,368 100 %$152,431 100 %$9,937 7 %

(in thousands)Nine Months Ended June 30, 2025% ofExpenseCategory Nine Months Ended June 30, 2024% ofExpenseCategory Increase (Decrease)$%Candidate costs$243,094 56 %$185,708 50 %$57,386 31 %R&D discovery costs48,785 11 %56,736 15 %(7,951)(14)%Salaries80,583 19 %72,048 19 %8,535 12 %Facilities related20,944 5 %19,597 7 %1,347 7 %Total research and development expense, excluding non-cash expense$393,406 91 %$334,089 91 %$59,317 18 %Stock compensation23,049 5 %23,735 6 %(686)(3)%Depreciation and amortization16,017 4 %12,220 3 %3,797 31 %Total research and development expense$432,472 100 %$370,044 100 %$62,428 17 %

Candidate costs increased $3.4 million, or 4%, for the three months ended June 30, 2025 compared to the same period of 2024, and $57.4 million, or 31%, for the nine months ended June 30, 2025 compared to the same period of 2024. The increase for both periods was primarily due to the additional progression of the Company’s pipeline of candidates into and through clinical trials, which resulted in higher manufacturing, outsourced clinical trial,